---
document_datetime: 2025-09-29 14:18:47
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bortezomib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: bortezomib-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 8.9079703
conversion_datetime: 2025-12-31 03:21:13.362547
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BortezomibAccord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                       | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| VariationtypeIA/    | A.ADMINISTRATIVECHANGES-A.7 | 25/09/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000301240                     | Deletion of manufacturing sitesfor an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place,orsupplierofastartingmaterial, reagent orexcipient(when mentioned in the dossier)*- Accepted                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     | PL   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000279397 | This was an application for a group of variations. B.1.b.2 Change in test procedurefor active substance or starting material/reagent/intermediateused inthe manufacturing process of the active substance-B.I.b.2.a Minor changes to an approved testprocedure-Accepted B.1.b.2 Change in testprocedurefor active substance or starting material/reagent/intermediateused in the manufacturing process of the active substance-B.I.b.2.a Minor changes to an approved test procedure-Accepted B.1.b.2 Change in testprocedurefor active substance or starting material/reagent/intermediateusedinthe manufacturing process of the active substance -B.I.b.2.a Minor changes to an approved test procedure-Accepted | 12/09/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

| B.I.a.3 Change inbatch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to10-foldincreasecomparedto the originally approvedbatch size-Accepted  B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in themanufacturingprocess of the active substance orchangeinthemanufacturer (including where relevant quality control testingsites)oftheactivesubstance,where noPh.Eur.Certificate ofSuitability ispart of the approved dossier-B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approvedmanufacturer-Accepted  B.1.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance-B.I.b.1.z Other changes-Accepted  B.1.b.2Changein testprocedureforactive substance or starting material/reagent/intermediateusedinthe manufacturing process of the active substance-B.I.b.2.e Otherchanges to a test procedure(includingreplacementor   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| addition)fortheactivesubstance or a startingmaterial/intermediate-Accepted  B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.e Minorchangetotherestrictedpartof an ActiveSubstance MasterFile-Accepted  B.1.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturingprocessoftheactive substance-B.1.b.2.e Other changesto a test procedure (including replacement or addition)fortheactivesubstance ora startingmaterial/intermediate-Accepted  B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4Extensionorintroductionofare- test period/storage period supported by real time data- Accepted  B.I.b.1 Change in the specification parameters and/or limits of an active substance,startingmaterial/intermediate/ reagent used in the manufacturing process of the active substance -B.I.b.1.b Tightening ofspecificationlimits-Accepted  B.I.d.1.b Storage conditions -B.I.d.1.b.1 Changetomorerestrictivestorage conditions of the active substance - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000266696   | This was an application for a group of variations. B.II.c.1 Change in the specification parameters and/or limits of an excipient - B.II.c.1.z Other changes-Accepted B.II.c.2Changeintestprocedureforan excipient - B.1I.c.2.d Other changes to a test procedure (including replacement or addition)-Accepted B.II.c.2 Change in test procedure for an excipient - B.1I.c.2.d Other changes to a test procedure(includingreplacementor addition) - Accepted B.II.c.2 Change in test procedure for an excipient - B.1I.c.2.d Other changes to a test procedure (including replacement or addition)-Accepted B.II.c.2 Change in test procedure for an excipient - B.11.c.2.d Other changes to a test procedure (including replacement or addition)- Accepted B.II.c.2 Change in test procedure for an excipient-B.1I.c.2.d Otherchanges to a test   | 16/06/2025   | N/A   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|                                       | addition) - Accepted B.II.c.2 Change in test procedure for an excipient-B.II.c.2.d Other changes to a test procedure (including replacement or addition)-Accepted B.II.c.2 Change in test procedure for an excipient - B.II.c.2.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |             |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type IB / EMA/VR/0000257066 | C.1.2 Change(s)in theSummary of Product Characteristics,Labelling orPackageLeaflet of ageneric/hybrid/biosimilarmedicinal productsfollowingassessmentofthesame change for the reference product - C.1.2.a Implementation of change(s) for which no new additional data is required to be submittedby theMAH-Accepted C.1.2.a-To update sections 4.6 and 5.3 of the SmPC and section 2 of the Package LeaflettoalignthePIwith theoneof the reference product (VELCADE 1 mg/3.5 mg powder for solution for injection) following adoptionofprocedure EMEA/H/C/000539/I1/0102.Additionally,the MAH has updated section 4.8, 5.1, 5.2 and leafletsections2,4witheditorialchanges in-line with reference product. Moreover, the MAHtooktheopportunitytoupdatethe | 31/03/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| contact details of the Greek representative as well as amending the country code for Luxembourg from \"LX\" to read as \"Lu\" in  section6of thePackageLeaflet.   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|